表紙
市場調查報告書

新一代測序 (NGS) 市場:服務提供者 (全基因組、全外顯子組、標靶測序)、技術平台

Next Generation Sequencing (NGS) Market, 2020-2030: Service Providers (Whole Genome, Whole Exome and Targeted Sequencing) and Technology Platforms

出版商 ROOTS ANALYSIS 商品編碼 919313
出版日期 內容資訊 英文 381 Pages
商品交期: 最快1-2個工作天內
價格
新一代測序 (NGS) 市場:服務提供者 (全基因組、全外顯子組、標靶測序)、技術平台 Next Generation Sequencing (NGS) Market, 2020-2030: Service Providers (Whole Genome, Whole Exome and Targeted Sequencing) and Technology Platforms
出版日期: 2019年12月31日內容資訊: 英文 381 Pages
簡介

DNA測序技術的發展,為精密醫療和診斷等各式各樣的醫療研究領域帶來極大進展。尤其是實現了全基因組及全外顯子組測序的新一代測序 (NGS) 的影響特別大,由於高產量篩選平行基因組測序技術,大幅降低了綜合成本及時間。雖然尚有缺乏高泛用性in silico工具等問題,但預計當問題解決後,該市場會有大幅成長。

本報告調查了新一代測序 (NGS) 技術及服務市場,並統整了NGS技術概要、發展經過、種類及用途、服務提供者 (企業、機構) 及技術供應者的分佈、主要企業檔案、臨床實驗及專利動態、民間企業及政府的倡議、技術&服務區分、用途、終端使用者、地區別市場規模變化與預測、未來市場機會分析等。

第1章 序文

第2章 執行摘要

第3章 簡介

  • 本章概要
  • 基因組測序的概要
  • 基因組測序的各種類型
  • 基因組測序的進步
    • 第1代DNA序列分析儀
    • 高產量篩選新一代測序 (HT-NGS)
      • 第2代HT-NGS平台
      • 第3代HT-NGS平台
  • 基因組測序的重要性
    • 單核甘酸多態性的同定
    • 大規模結構變異的同定
    • 多態性、變異體的品質管理與基因驗證
    • Haplotype Phasing
    • 基因組測序技術的比較
  • 基因組測序的用途
    • 癌症相關生物標記研究
    • 診斷
    • 個別化醫療、精密醫療
    • 法醫學
  • 基因組測序的課題
  • 未來展望

第4章 基因組測序服務提供者:市場環境

  • 本章概要
  • 基因組測序服務提供者:企業
    • 設立年別
    • 企業規模別
    • 所在地別
    • 提供服務類型別
      • 全基因組測序服務
      • 全外顯子組測序服務
      • 標靶測序服務
  • 基因組測序服務提供者:機構
    • 設立年別
    • 所在地別
    • 服務類型別
      • 全基因組測序服務
      • 全外顯子組測序服務
      • 標靶測序服務

第5章 基因組測序技術:市場環境

  • 本章概要
  • 基因組測序技術
    • 用途別
    • 最大測序輸出別
    • 每欄最大lead別
    • 測序技術別
    • 設立年別
    • 企業規模別
    • 所在地別

第6章 平台競爭分析

第7章 企業檔案:基因組測序服務提供者

  • 本章概要
  • Admera Health
  • Applied Biological Materials
  • BGI Genomics
  • CD Genomics
  • DNA Link
  • Eurofins Genomics (Eurofins Scientific)
  • Fulgent Genetics
  • Gene by Gene
  • GENEWIZ
  • MedGenome
  • Novogene
  • Omega Biosciences
  • Psomagen
  • Veritas Genetics
  • Xcerlis Labs

第8章 企業檔案:基因組測序技術提供者

  • 本章概要
  • Illumina
  • Oxford Nanopore Technologies
  • Thermo Fisher Scientific

第9章 專利分析

第10章 臨床實驗分析

第11章 大型製藥公司的基因組測序相關倡議

第12章 案例研究:政府倡議

第13章 市場預測

  • 本章概要
  • 總市場預測
  • 市場預測:主要區分別
    • 產品市場:技術類型別
    • 服務市場:服務類型別
  • 市場預測:用途別
  • 市場預測:終端用途別
  • 市場預測:地區別
    • 北美洲
    • 歐洲
    • 亞洲及太平洋
    • 其他地區

第14章 未來市場機會

第15章 附錄1

第16章 附錄2

目錄

Example Insights:

Till date, close to 2,600 trials, involving the use of genome sequencing data for a variety of applications, have been registered across different therapeutic areas and geographical locations.

Overview:

Advances in DNA sequencing technologies have led to significant developments in a variety of healthcare-focused research fields, such as precision medicine and diagnostics. Particularly, the impact of next generation sequencing (NGS) methods, enabling whole genome and whole exome sequencing, has been the most profound. This high throughput, parallel genome sequencing technology has greatly reduced the overall cost and time investment. In fact, compared to the Human Genome Project (~USD 3 billion), the cost of sequencing a single genome has decreased to USD 1,000, using currently available technologies. Owing to the ongoing innovation in this field, stakeholders believe that the aforementioned cost may get further reduced to USD 100 over the next decade. This decrease in genome sequencing costs has led to a marked increase in the number of genomes being sequenced around the world. In fact, several large scale efforts, such as UK Biobank and GenomeAsia 100k, have been initiated in order to collect genomic data for use in medical research. Big pharma players, including AstraZeneca, GSK, Pfizer, Merck and Roche, are actively on the lookout for collaborating with such data repositories in order to access the aforementioned information.

Despite the progress made in this field of research, there are several existing challenges related to the NGS process affiliated workflow and data analysis. The lack of versatile in silico tools is considered to be the major rate-limiting step in NGS data analysis and interpretations. At present, industry stakeholders are actively collaborating in order to integrate their respective resources for mining these large and complex datasets to generate clinically relevant, actionable insights. Additionally, there is a need for better genomic library preparation protocols, which required less starting material, and are capable of generating libraries with more precisely estimated insert sizes and longer reads at reduced error rates. More efficient genome assembly algorithms and better processors (increased computational power) for genomic data processing are also likely to get developed. We are led to believe that, once the aforementioned challenges are addressed, this segment of the biopharmaceutical industry will witness significant growth.

Scope of the Report:

The ‘Next Generation Sequencing (NGS) Market, 2020-2030: Service Providers (Whole Genome, Whole Exome and Targeted Sequencing) and Technology Platforms' report features an extensive study of the current landscape and the future opportunities associated with service / technologies providers. Amongst other elements, the report features:

  • An overview of the genome sequencing service providers landscape, featuring information on year of establishment, company size, geographical location and types of services offered (sanger sequencing, genotyping, whole genome sequencing, whole exome sequencing targeted sequencing and bioinformatics). Further, it provides details on the cost of services, sequencing systems used, average turn-around time and sequencing coverage, for certain types of sequencing-related services (whole genome, whole exome and targeted sequencing) offered by contract service providers.
  • An overview of genome sequencing technologies landscape, featuring information on type of applications, run time, maximum reads per run, maximum sequencing output, maximum read length, type of sequencing technique, quality score and cost. It also provides information on the technology providers involved in this domain, including information on year of establishment, company size and geographical location.
  • An informed competitiveness analysis of the genome sequencing technologies captured in our database, taking into consideration relevant parameters, such as supplier power (based on company size of technology provider) and other important technology-related specifications, such as types of applications, maximum sequencing output, maximum reads per run, maximum read length, quality score and cost of sequencer.
  • An in-depth analysis of intellectual property related to this field of research, in order to generate an opinion on how the industry has evolved from the R&D perspective. The analysis takes into consideration genome sequencing-related patents that have been filed / granted since 2015, highlighting publication year, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players, patent characteristics and geography.
  • An analysis of completed, ongoing and planned clinical studies related to genome sequencing, featuring details on registration year, type of sponsors / collaborators, current status of trials, type of study design, target therapeutic area, type of application, regional distribution of clinical trials and enrolled patient population.
  • An analysis of the various genome sequencing-focused initiatives of the ten big pharma players (shortlisted based on extent of activity in genome sequencing domain), highlighting the key focus areas of such companies along with information on funding, collaboration and acquisition activity.
  • A case study on the various national and international, government sponsored initiatives related to genome sequencing, analyzed on the basis of year of initiation, type of investors, type of participant organization, research objectives, geographical distribution, region-specific data access policies and key focus areas of research.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity within the genome sequencing services and technologies market. Based on several parameters, such as number of genomes sequenced annually, average cost of sequencing, revenues generated by major players and expected annual growth rate, we have provided an informed estimate of the likely evolution of the market, for the period 2020-2030. The chapter also presents a detailed segmentation of the aforementioned opportunity across [A] key application areas (diagnostics, drug discovery, precision medicine and others), [B] end-users (hospitals and clinics, academics and research institutes, pharmaceuticals companies and others), [C] types of technologies (sequencing by synthesis, ion semiconductor, single-molecule real-time sequencing, nanopore and others), [D] types of services (whole genome sequencing, whole exome sequencing and targeted sequencing) and [E] key geographical regions (North America, Asia-Pacific, Europe, and rest of the world).

In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain. In addition, the report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names):

  • Michael Powell (Chief Scientific Officer, DiaCarta)
  • Mike Klein (Chief Executive Officer, Genomenon)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Chapter Outlines:

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the genome sequencing services and technology providers market in the mid to long term.

Chapter 3 provides a general overview of the concept of genome sequencing with information on its process workflow, types including whole genome, whole exome and targeted sequencing, epigenetics, metagenomics and RNA sequencing and a wide array of uses in clinical research. It further highlights the history and evolution of genome sequencing with details on first, second and third generation NGS platforms, and a brief outline of various applications of genome sequencing including cancer and biomarker research, precision medicine, diagnostics and forensics research. Further, it includes a discussion on the various limitations / constraints and future perspectives of this evolving segment of pharmaceutical industry.

Chapter 4 provides an overview of genome sequencing service providers landscape, featuring information on year of establishment, company size, geographical location and types of services offered (sanger sequencing, genotyping, whole genome sequencing, whole exome sequencing targeted sequencing and bioinformatics). Further, it provides details on the cost of services, sequencing systems used, average turn-around time and sequencing coverage, for certain types of sequencing-related services (whole genome, whole exome and targeted sequencing) offered by contract service providers.

Chapter 5 provides an overview of genome sequencing technologies landscape, featuring information on the type of applications, run time, maximum reads per run, maximum sequencing output, maximum read length, type of sequencing technique, quality score and cost. It also provides information on the technology providers involved in this domain, including information on year of establishment, company size and geographical location.

Chapter 6 provides an informed competitiveness analysis of the genome sequencing technologies captured in our database, taking into consideration relevant parameters, such as supplier power (based on company size of technology provider) and other important technology-related specifications, such as types of applications, maximum sequencing output, maximum reads per run, maximum read length, quality score and cost of sequencer.

Chapter 7 includes brief profiles of prominent service providers engaged in this domain. Each profile provides a brief overview of the company, its financial information (if available), a detailed description of services offered, recent developments and an informed future outlook.

Chapter 8 includes brief profiles of prominent technology developers engaged in this domain, featuring an overview of the company, its financial information (if available), a detailed description of its proprietary technology platform(s), recent developments and an informed future outlook.

Chapter 9 provides an in-depth patent analysis to provide an overview on how the industry has evolved from the R&D perspective. For this analysis, we looked at the patents related to genome sequencing that have been published since 2015. The analysis also highlights key information associated with these patents, including publication year, issuing authority / patent offices involved, CPC symbols, emerging focus areas, leading players, patent characteristics and geography.

Chapter 10 provides an analysis of completed, ongoing and planned clinical studies related to genome sequencing. The trials were analyzed on the basis of various relevant parameters, such as on registration year, type of sponsors / collaborators, current status of trials, type of study design, target therapeutic area, type of application, regional distribution of clinical trials and enrolled patient population.

Chapter 11 presents an analysis of the various genome sequencing-focused initiatives of ten big pharma players (out of top 20 established pharmaceutical players), highlighting the key focus areas of such companies along with information on funding, collaboration and acquisition activity.

Chapter 12 presents a case study on various national and international government sponsored initiatives related to genome sequencing, analyzed on the basis of year of initiation, type of investors, type of participant organization, research objectives, geographical distribution, region-specific data access policies and key focus areas of research.

Chapter 13 presents a detailed market forecast, highlighting the future potential of the genome sequencing services and technology market till the year 2030. The chapter features the likely distribution of the opportunity across [A] application areas (diagnostics, drug discovery, precision medicine and others), [B] end-users (hospitals and clinics, academics and research institutes, pharmaceuticals companies and others), [C] types of technologies (sequencing by synthesis, ion semiconductor, single-molecule real-time sequencing, nanopore and others), [D] types of services (whole genome sequencing, whole exome sequencing and targeted sequencing) and [E] key geographical regions (North America, Asia-Pacific, Europe, and rest of the world).

Chapter 14 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it summarizes the various evolutionary trends that are likely to influence the future of this market.

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 16 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Genome Sequencing
  • 3.3. Types of Genome Sequencing
  • 3.4. History and Evolution of Genome Sequencing
    • 3.4.1. First Generation DNA Sequencers
    • 3.4.2. High Throughput-Next Generation Sequencing (HT-NGS)
      • 3.4.2.1. Second Generation HT-NGS Platforms
      • 3.4.2.2. Third Generation HT-NGS Platforms
        • 3.4.2.2.1. Heliscope™ Single Molecule Sequencer
        • 3.4.2.2.2. Single Molecule Real Time (SMRT™) Sequencer
        • 3.4.2.2.3. Single Molecule Real Time (RNAP) Sequencer
        • 3.4.2.2.4. Nanopore DNA Sequencer
        • 3.4.2.2.5. Multiplex Polony Technology
        • 3.4.2.2.6. The Ion Torrent Sequencing Technology
  • 3.5. Practical Relevance of Genome Sequencing
    • 3.5.1. Identification of Single Nucleotide Variants
    • 3.5.2. Identification of Large Structural Variants
    • 3.5.3. Variant Quality Control and Genotype Validation
    • 3.5.4. Haplotype Phasing
    • 3.5.3. Comparison of Available Genome Sequencing Technologies
  • 3.6. Applications of Genome Sequencing
    • 3.6.1. Cancer and Affiliated Biomarker Research
    • 3.6.2. Diagnostics
    • 3.6.3. Personalized / Precision Medicine
    • 3.6.4. Forensics
  • 3.7. Challenges Associated with Genome Sequencing
  • 3.8. Future Perspectives

4. GENOME SEQUENCING SERVICE PROVIDERS: MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Genome Sequencing Service Providers: Market Landscape of Industry Players
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Geographical Location
    • 4.2.4. Analysis by Type of Services Offered
      • 4.2.4.1. Whole Genome Sequencing Services
      • 4.2.4.2. Whole Exome Sequencing Services
      • 4.2.4.3. Targeted Sequencing Services
  • 4.3. Genome Sequencing Service Providers: Market Landscape of Non-Industry Players
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.3. Analysis by Geographical Location
    • 4.3.4. Analysis by Type of Services
      • 4.3.4.1. Whole Genome Sequencing Services
      • 4.3.4.2. Whole Exome Sequencing Services
      • 4.3.4.3. Targeted Sequencing Services

5. GENOME SEQUENCING TECHNOLOGIES: MARKET LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. Genome Sequencing Technologies: Overall Market Landscape
    • 5.2.1. Analysis by Type of Application
    • 5.2.2. Analysis by Maximum Sequencing Output
    • 5.2.3. Analysis by Maximum Reads per Run
    • 5.2.4. Analysis by Type of Sequencing Technique
    • 5.2.5. Analysis of Technology Providers by Year of Establishment
    • 5.2.6. Analysis of Technology Providers by Company Size
    • 5.2.7. Analysis of Technology Providers by Geographical Location

6. PLATFORM COMPETITIVENESS ANALYSIS

  • 6.1. Chapter Overview
  • 6.2. Methodology and Key Parameters
    • 6.2.1. Platform Competitiveness Analysis: Peer Group I
    • 6.2.2. Platform Competitiveness Analysis: Peer Group II
    • 6.2.3. Platform Competitiveness Analysis: Peer Group III
    • 6.2.4. Platform Competitiveness Analysis: Peer Group IV

7. COMPANY PROFILES: GENOME SEQUENCING SERVICE PROVIDERS

  • 7.1. Chapter Overview
  • 7.2. Admera Health
    • 7.2.1. Company Overview
    • 7.2.2. Service Portfolio
    • 7.2.3. Recent Developments and Future Outlook
  • 7.3. Applied Biological Materials
    • 7.3.1. Company Overview
    • 7.3.2. Services Portfolio
    • 7.3.3. Recent Developments and Future Outlook
  • 7.4. BGI Genomics
    • 7.4.1. Company Overview
    • 7.4.2. Services Portfolio
    • 7.4.3. Recent Developments and Future Outlook
  • 7.5. CD Genomics
    • 7.5.1. Company Overview
    • 7.5.2. Services Portfolio
    • 7.5.3. Recent Developments and Future Outlook
  • 7.6. DNA Link
    • 7.6.1. Company Overview
    • 7.6.2. Services Portfolio
    • 7.6.3. Recent Developments and Future Outlook
  • 7.7. Eurofins Genomics (Eurofins Scientific)
    • 7.7.1. Company Overview
    • 7.7.2. Services Portfolio
    • 7.7.3. Recent Developments and Future Outlook
  • 7.8. Fulgent Genetics
    • 7.8.1. Company Overview
    • 7.8.2. Services Portfolio
    • 7.8.3. Recent Developments and Future Outlook
  • 7.9. Gene by Gene
    • 7.9.1. Company Overview
    • 7.9.2. Services Portfolio
    • 7.9.3. Recent Developments and Future Outlook
  • 7.10. GENEWIZ
    • 7.10.1. Company Overview
    • 7.10.2. Services Portfolio
    • 7.10.3. Recent Developments and Future Outlook
  • 7.11. MedGenome
    • 7.11.1. Company Overview
    • 7.11.2. Services Portfolio
    • 7.11.3. Recent Developments and Future Outlook
  • 7.12. Novogene
    • 7.12.1. Company Overview
    • 7.12.2. Services Portfolio
    • 7.12.3. Recent Developments and Future Outlook
  • 7.13. Omega Biosciences
    • 7.13.1. Company Overview
    • 7.13.2. Services Portfolio
    • 7.13.3. Recent Developments and Future Outlook
  • 7.14. Psomagen
    • 7.14.1. Company Overview
    • 7.14.2. Services Portfolio
    • 7.14.3. Recent Developments and Future Outlook
  • 7.15. Veritas Genetics
    • 7.15.1. Company Overview
    • 7.15.2. Services Portfolio
    • 7.15.3. Recent Developments and Future Outlook
  • 7.16. Xcerlis Labs
    • 7.16.1. Company Overview
    • 7.16.2. Services Portfolio
    • 7.16.3. Recent Developments and Future Outlook

8. COMPANY PROFILES: GENOME SEQUENCING TECHNOLOGY PROVIDERS

  • 8.1. Chapter Overview
  • 8.2. Illumina
    • 8.2.1. Company Overview
    • 8.2.2. Financial Information
    • 8.2.3. Product Portfolio
      • 8.2.3.1. iSeq 100™ System
      • 8.2.3.2. MiniSeq™ System
      • 8.2.3.3. MiSeq® System
      • 8.2.3.4. NextSeq® Series
      • 8.2.3.5. NextSeq 6000® System
    • 8.2.4. Recent Developments and Future Outlook
  • 8.3. Oxford Nanopore Technologies
    • 8.3.1. Company Overview
    • 8.3.2. Financial Information
    • 8.3.3. Product Portfolio
      • 8.3.3.1. MinION™ System
      • 8.3.3.2. GridION™ System
      • 8.3.3.3. PromethION™ System
    • 8.3.4. Recent Developments and Future Outlook
  • 8.4. Thermo Fisher Scientific
    • 8.4.1. Company Overview
    • 8.4.2. Financial Information
    • 8.4.3. Product Portfolio
      • 8.4.3.1. Ion S5™ Systems
      • 8.4.3.2. Ion GeneStudio S5™ System
      • 8.4.3.3. SeqStudio™ System
      • 8.4.3.4. Applied Biosystems® 3500 System
      • 8.4.3.5. Ion PGM™ System
      • 8.4.3.6. Ion Proton™ System
    • 8.4.4. Recent Developments and Future Outlook

9. PATENT ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Scope and Methodology
  • 9.3. Genome Sequencing: Analysis of Patent Portfolio
    • 9.3.1. Analysis by Publication Year
    • 9.3.2. Analysis by Issuing Authority / Patent Offices Involved
    • 9.3.3. Analysis by CPC Symbols
  • 9.4. Emerging Focus Areas
  • 9.5. Leading Players: Analysis by Number of Patents
  • 9.6. Genome Sequencing: Patent Benchmarking Analysis
    • 9.6.1. Analysis by Patent Characteristics
    • 9.6.2. Analysis by Geography
  • 9.7. Patent Valuation Analysis

10. CLINICAL TRIAL ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Genome Sequencing: Clinical Trial Analysis
    • 10.3.1. Analysis by Trial Registration Year
    • 10.3.2. Analysis by Trial Registration Year and Geography
    • 10.3.3. Analysis by Type of Sponsors / Collaborators
    • 10.3.4. Analysis by Trial Status
    • 10.3.5. Analysis by Trial Phase
    • 10.3.6. Analysis by Type of Study Design
    • 10.3.7. Analysis by Target Therapeutic Area
    • 10.3.8. Analysis by Type of Application
    • 10.3.10. Analysis by Target Therapeutic Area and Type of Application
    • 10.3.11. Analysis by Number of Trials and Geography
    • 10.3.12. Analysis by Enrolled Patient Population and Geography
    • 10.3.13. Analysis by Number of Trials, Trial Status and Geography
    • 10.3.14. Analysis by Enrolled Patient Population, Trial Status and Geography

11. GENOME SEQUENCING RELATED INITIATIVES OF BIG PHARMA PLAYERS

  • 11.1. Chapter Overview
  • 11.2. Scope and Methodology
    • 11.2.1. Analysis by Type of Initiative
    • 11.2.2. Analysis by Type of Collaboration
    • 11.2.3. Analysis by Focus Area
    • 11.2.4. Leading Players: Analysis by Number of Initiatives

12. CASE STUDY: GOVERNMENT SPONSORED INITIATIVES

  • 12.1. Chapter Overview
  • 12.2. Government Sponsored Initiatives
    • 12.2.1. Analysis by Study Status
    • 12.2.2. Analysis by Study Start Year
    • 12.2.3. Analysis by Geographical Scope
    • 12.2.4. Analysis of National Initiatives by Geographical Location, Year and Number of Genomes Sequenced
    • 12.2.5. Analysis by Research Objective
    • 12.2.6. Analysis by Focus Area
    • 12.2.7. Analysis by Type of Players
    • 12.2.8. Analysis by Type of Investors
    • 12.2.9. Analysis by Region-specific Data Accessibility

13. MARKET FORECAST

  • 13.1. Chapter Overview
  • 13.2. Overall Next Generation Sequencing Market, 2020-2030
  • 13.3. Next Generation Sequencing Market: Distribution across Key Market Segments, 2020-2030
    • 13.3.1. Genome Sequencing Products Market: Distribution by Type of Technology,2020 and 2030
    • 13.3.2. Genome Sequencing Services Market: Distribution by Type of Service, 2020 and 2030
  • 13.4. Next Generation Sequencing Market: Distribution by Application Area, 2020 and 2030
  • 13.5. Next Generation Sequencing Market: Distribution by End-Users, 2020 and 2030
  • 13.6. Next Generation Sequencing Market: Distribution by Geographical Regions, 2020 and 2030
    • 13.6.1. Next Generation Sequencing Market in North America, 2020-2030
      • 13.6.1.1. Next Generation Sequencing Market in North America: Distribution by Application Area, 2020-2030
        • 13.6.1.1.1. Next Generation Sequencing Market for Diagnostics in North America, 2020-2030
        • 13.6.1.1.2. Next Generation Sequencing Market for Drug Discovery in North America, 2020-2030
        • 13.6.1.1.3. Next Generation Sequencing Market in for Precision Medicine in North America, 2020-2030
        • 13.6.1.1.4. Next Generation Sequencing Market in for Other Application Areas in North America, 2020-2030
      • 13.6.1.2. Next Generation Sequencing Market in North America: Distribution by End-Users,2020-2030
        • 13.6.1.2.1. Next Generation Sequencing Market for Hospitals and Clinics in North America, 2020-2030
        • 13.6.1.2.2. Next Generation Sequencing Market for Academic and Research Institutes in North America, 2020-2030
        • 13.6.1.2.3. Next Generation Sequencing Market for Pharmaceutical Companies in North America, 2020-2030
        • 13.6.1.2.4. Next Generation Sequencing Market for Other Users in North America, 2020-2030
    • 13.6.2. Next Generation Sequencing Market in Europe, 2020-2030
      • 13.6.2.1. Next Generation Sequencing Market in Europe: Distribution by Application Area, 2020-2030
        • 13.6.2.1.1. Next Generation Sequencing Market for Diagnostics in Europe, 2020-2030
        • 13.6.2.1.2. Next Generation Sequencing Market for Drug Discovery in Europe, 2020-2030
        • 13.6.2.1.3. Next Generation Sequencing Market for Precision Medicine in Europe, 2020-2030
        • 13.6.2.1.4. Next Generation Sequencing Market in for Other Application Areas in Europe, 2020-2030
      • 13.6.2.2. Next Generation Sequencing Market in Europe: Distribution by End-Users, 2020-2030
        • 13.6.2.2.1. Next Generation Sequencing Market for Hospitals and Clinics in Europe, 2020- 2030
        • 13.6.2.2.2. Next Generation Sequencing Market for Academic and Research Institutes in Europe, 2020-2030
        • 13.6.2.2.3. Next Generation Sequencing Market for Pharmaceutical Companies in Europe, 2020-2030
        • 13.6.2.2.4. Next Generation Sequencing Market for Other Users in Europe, 2020-2030
    • 13.6.3. Next Generation Sequencing Market in Asia-Pacific, 2020-2030
      • 13.6.3.1. Next Generation Sequencing Market in Asia-Pacific: Distribution by Application Area, 2020-2030
        • 13.6.3.1.1. Next Generation Sequencing Market for Diagnostics in Asia-Pacific, 2020-2030
        • 13.6.3.1.2. Next Generation Sequencing Market for Drug Discovery in Asia-Pacific, 2020-2030
        • 13.6.3.1.3. Next Generation Sequencing Market for Precision Medicine in Asia-Pacific, 2020-2030
        • 13.6.3.1.4. Next Generation Sequencing Market for Other Application Areas in Asia-Pacific, 2020-2030
      • 13.6.3.2. Next Generation Sequencing Market in Asia-Pacific: Distribution by End-Users 2020-2030
        • 13.6.3.2.1. Next Generation Sequencing Market for Hospitals and Clinics in Asia-Pacific, 2020-2030
        • 13.6.3.2.2. Next Generation Sequencing Market for Academic and Research Institutes in Asia-Pacific, 2020-2030
        • 13.6.3.2.3. Next Generation Sequencing Market for Pharmaceutical Companies in Asia-Pacific, 2020-2030
        • 13.6.3.2.4. Next Generation Sequencing Market for Other Users in Asia-Pacific, 2020-2030
    • 13.6.4. Next Generation Sequencing Market in Rest of the World, 2020-2030
      • 13.6.4.1. Next Generation Sequencing Market in Rest of the World: Distribution by Application Area, 2020-2030
        • 13.6.4.1.1. Next Generation Sequencing Market for Diagnostics in Rest of the World, 2020-2030
        • 13.6.4.1.2. Next Generation Sequencing Market for Drug Discovery in Rest of the World, 2020-2030
        • 13.6.4.1.3. Next Generation Sequencing Market for Precision Medicine in Rest of the World, 2020-2030
        • 13.6.4.1.4. Next Generation Sequencing Market for Other Application Areas in Rest of the World, 2020-2030
      • 13.6.4.2. Next Generation Sequencing Market in Rest of the World: Distribution by End-Users, 2020-2030
        • 13.6.4.2.1. Next Generation Sequencing Market for Hospitals and Clinics in Rest of the World, 2020-2030
        • 13.6.4.2.2. Next Generation Sequencing Market for Academic and Research Institutes in Rest of the World, 2020-2030
        • 13.6.4.2.3. Next Generation Sequencing Market for Pharmaceutical Companies in Rest of the World, 2020-2030
        • 13.6.4.2.4. Next Generation Sequencing Market for Other Users in Rest of the World, 2020-2030

14. FUTURE OPPORTUNITIES

15. APPENDIX 1: TABULATED DATA

16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

  • Figure 3.1: Steps Involved in Genome Sequencing
  • Figure 3.2: Types of Genome Sequencing
  • Figure 3.3: Types of Third Generation Sequencing Technologies
  • Figure 3.4: Applications of Genome Sequencing
  • Figure 4.1: Genome Sequencing Service Providers (Industry Players): Distribution by Year of Establishment
  • Figure 4.2: Genome Sequencing Service Providers (Industry Players): Distribution by Company Size
  • Figure 4.3: Genome Sequencing Service Providers (Industry Players): Distribution by Geography
  • Figure 4.4: Genome Sequencing Service Providers (Industry Players): Distribution by Type of Services Offered
  • Figure 4.5: Whole Genome Sequencing Services (Industry Players): Distribution by Technology Used
  • Figure 4.6: Whole Exome Sequencing Services (Industry Players): Distribution by Technology Used
  • Figure 4.7: Targeted Sequencing Services (Industry Players): Distribution by Technology Used
  • Figure 4.8: Genome Sequencing Service Providers (Non-Industry Players): Distribution by Year of Establishment
  • Figure 4.9: Genome Sequencing Service Providers (Non-Industry Players): Distribution by Geography
  • Figure 4.10: Genome Sequencing Service Providers (Non-Industry Players): Distribution by Type of Services Offered
  • Figure 4.11: Whole Genome Sequencing Services (Non-Industry Players): Distribution by Technology Used
  • Figure 4.12: Whole Exome Sequencing Services (Non-Industry Players): Distribution by Technology Used
  • Figure 4.13: Targeted Sequencing Services (Non-Industry Players): Distribution by Technology Used
  • Figure 5.1: Genome Sequencing Technologies: Distribution by Type of Application
  • Figure 5.2: Genome Sequencing Technologies: Distribution by Maximum Sequencing Output
  • Figure 5.3: Genome Sequencing Technologies: Distribution by Maximum Reads per Run
  • Figure 5.4: Genome Sequencing Technologies: Distribution by Sequencing Technique
  • Figure 5.5: Genome Sequencing Technology Providers: Distribution by Year of Establishment
  • Figure 5.6: Genome Sequencing Technology Providers: Distribution by Company Size
  • Figure 5.7: Genome Sequencing Technology Providers: Distribution by Geography
  • Figure 6.1: Platform Competitiveness Analysis: Peer Group I
  • Figure 6.2: Platform Competitiveness Analysis: Peer Group II
  • Figure 6.3: Platform Competitiveness Analysis: Peer Group III
  • Figure 6.4: Platform Competitiveness Analysis: Peer Group IV
  • Figure 8.1: Illumina: Annual Revenues, 2013- Q32020 (USD Million)
  • Figure 8.2: Illumina: Product Portfolio
  • Figure 8.3: Oxford Nanopore Technologies: Product Portfolio
  • Figure 8.4: Thermo Fisher Scientific: Annual Revenues, 2013-Q32020 (USD Million)
  • Figure 8.5: Thermo Fisher Scientific: Product Portfolio
  • Figure 9.1: Patent Portfolio: Distribution by Type of Patent
  • Figure 9.2: Patent Portfolio: Cumulative Distribution by Publication Year
  • Figure 9.4: Patent Portfolio: Distribution by Geographical Region
  • Figure 9.5: Patent Portfolio: Distribution by CPC Symbols
  • Figure 9.6: Patent Portfolio: Emerging Focus Areas
  • Figure 9.7: Leading Players: Distribution by Size of Patent Portfolio
  • Figure 9.8: Patent Portfolio: Benchmarking by Patent Characteristics
  • Figure 9.9: Patent Portfolio: Benchmarking by International Patents
  • Figure 9.1: Patent Portfolio: Distribution by Geography and Type of Patent
  • Figure 9.11: Patent Portfolio: Distribution by Patent Age
  • Figure 9.12: Patent Portfolio: Valuation Analysis
  • Figure 10.1: Clinical Trial Analysis: Cumulative Distribution of Number of Trials by Trial Registration Year
  • Figure 10.2: Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
  • Figure 10.3: Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Study Start Year
  • Figure 10.4: Clinical Trial Analysis: Distribution by Type of Sponsors / Collaborators
  • Figure 10.5: Clinical Trial Analysis: Distribution by Trial Status
  • Figure 10.6: Clinical Trial Analysis: Distribution by Type of Study Design
  • Figure 10.7: Clinical Trial Analysis: Distribution by Target Therapeutic Area
  • Figure 10.8: Clinical Trial Analysis: Distribution by Type of Application
  • Figure 10.9: Clinical Trial Analysis: Distribution by Target Therapeutic Area and Type of Application
  • Figure 10. 1: Clinical Trial Analysis: Distribution by Number of Trials and Geography
  • Figure 10.11: Clinical Trial Analysis: Distribution by Enrolled Patient Population and Geography
  • Figure 10.12: Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geography
  • Figure 10.13: Clinical Trial Analysis: Distribution by Enrollment Patient Population, Trial Status and Geography
  • Figure 11.1: Big Pharma Initiatives: Distribution by Type of Initiative
  • Figure 11.2: Big Pharma Initiatives: Heat Map Analysis based on Type of Initiative
  • Figure 11.3: Big Pharma Initiatives: Distribution by Type of Collaboration
  • Figure 11.4: Big Pharma Initiatives: Heat Map Analysis based on Type of Collaboration
  • Figure 11.5: Big Pharma Initiatives: Distribution by Focus Area
  • Figure 11.6: Big Pharma Initiatives: Heat Map Analysis based on Focus Area
  • Figure 11.7: Leading Players: Distribution by Number of Initiatives
  • Figure 12.1: Government Sponsored Initiatives: Distribution by Study Status
  • Figure 12.2: Government Sponsored Initiatives: Distribution by Study Start Year
  • Figure 12.3: Government Sponsored Initiatives: Distribution by Geographical Scope
  • Figure 12.4: World Map Analysis of National Initiatives by Geographical Location, Year and Number of Genomes Sequenced
  • Figure 12.5: Government Sponsored Initiatives: Distribution by Research Objective
  • Figure 12.6: Government Sponsored Initiatives: Distribution by Focus Area
  • Figure 12.7: Government Sponsored Initiatives: Distribution by Type of Players
  • Figure 12.8: Government Sponsored Initiatives: Distribution by Type of Investors
  • Figure 13.1: Overall Next Generation Sequencing Market, 2020-2030 (USD Billion)
  • Figure 13.2: Next Generation Sequencing Market: Distribution by Key Market Segments, 2020-2030 (USD Billion)
  • Figure 13.3: Genome Sequencing Products Market: Distribution by Type of Technology, 2020 and 2030 (USD Billion)
  • Figure 13.4: Genome Sequencing Services Market: Distribution by Type of Service, 2020 and 2030 (USD Billion)
  • Figure 13.5: Next Generation Sequencing Market: Distribution by Application Area, 2020 and 2030 (USD Billion)
  • Figure 13.6: Next Generation Sequencing Market: Distribution by End-Users, 2020 and 2030 (USD Billion)
  • Figure 13.7: Next Generation Sequencing Market: Distribution by Geographical Regions, 2020 and 2030 (USD Billion)
  • Figure 13.8: Next Generation Sequencing Market in North America, 2020-2030 (USD Billion)
  • Figure 13.9: Next Generation Sequencing Market in North America: Distribution by Application Area, 2020-2030 (USD Billion)
  • Figure 13.10: Next Generation Sequencing Market for Diagnostics in North America, 2020-2030 (USD Billion)
  • Figure 13.11: Next Generation Sequencing Market for Drug Discovery in North America, 2020-2030 (USD Billion)
  • Figure 13.12: Next Generation Sequencing Market in for Precision Medicine in North America, 2020-2030 (USD Billion)
  • Figure 13.13: Next Generation Sequencing Market in for Other Application Areas in North America, 2020-2030 (USD Billion)
  • Figure 13.14: Next Generation Sequencing Market in North America: Distribution by End-Users, 2020-2030 (USD Billion)
  • Figure 13.15: Next Generation Sequencing Market for Hospitals and Clinics in North America, 2020-2030 (USD Billion)
  • Figure 13.16: Next Generation Sequencing Market for Academic and Research Institutes in North America, 2020-2030 (USD Billion)
  • Figure 13.17: Next Generation Sequencing Market for Pharmaceutical Companies in North America, 2020-2030 (USD Billion)
  • Figure 13.18: Next Generation Sequencing Market for Other Users in North America, 2020-2030 (USD Billion)
  • Figure 13.19: Next Generation Sequencing Market in Europe, 2020-2030 (USD Billion)
  • Figure 13.20: Next Generation Sequencing Market in Europe: Distribution by Application Area, 2020-2030 (USD Billion)
  • Figure 13.21: Next Generation Sequencing Market for Diagnostics in Europe, 2020-2030 (USD Billion)
  • Figure 13.22: Next Generation Sequencing Market for Drug Discovery in Europe, 2020-2030 (USD Billion)
  • Figure 13.23: Next Generation Sequencing Market for Precision Medicine in Europe, 2020-2030 (USD Billion)
  • Figure 13.24: Next Generation Sequencing Market in for Other Application Areas in Europe, 2020-2030 (USD Billion)
  • Figure 13.25: Next Generation Sequencing Market in Europe: Distribution by End Users, 2020- 2030 (USD Billion)
  • Figure 13.26: Next Generation Sequencing Market for Hospitals and Clinics in Europe, 2020- 2030 (USD Billion)
  • Figure 13.27: Next Generation Sequencing Market for Academic and Research Institutes in Europe, 2020-2030 (USD Billion)
  • Figure 13.28: Next Generation Sequencing Market for Pharmaceutical Companies in Europe, 2020-2030 (USD Billion)
  • Figure 13.29: Next Generation Sequencing Market for Other Users in Europe, 2020-2030 (USD Billion)
  • Figure 13.30: Next Generation Sequencing Market in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.31: Next Generation Sequencing Market in Asia-Pacific: Distribution by Application Area, 2020-2030 (USD Billion)
  • Figure 13.32: Next Generation Sequencing Market for Diagnostics in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.33: Next Generation Sequencing Market for Drug Discovery in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.34: Next Generation Sequencing Market for Precision Medicine in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.35: Next Generation Sequencing Market for Other Application Areas in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.36: Next Generation Sequencing Market in Asia-Pacific: Distribution by End-Users 2020-2030 (USD Billion)
  • Figure 13.37: Next Generation Sequencing Market for Hospitals and Clinics in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.38: Next Generation Sequencing Market for Academic and Research Institutes in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.39: Next Generation Sequencing Market for Pharmaceutical Companies in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.40: Next Generation Sequencing Market for Other Users in Asia-Pacific, 2020-2030 (USD Billion)
  • Figure 13.41: Next Generation Sequencing Market in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.42: Next Generation Sequencing Market in Rest of the World: Distribution by Application Area, 2020-2030 (USD Billion)
  • Figure 13.43: Next Generation Sequencing Market for Diagnostics in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.44: Next Generation Sequencing Market for Drug Discovery in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.45: Next Generation Sequencing Market for Precision Medicine in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.46: Next Generation Sequencing Market for Other Application Areas in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.47: Next Generation Sequencing Market in Rest of the World: Distribution by End-Users, 2020-2030 (USD Billion)
  • Figure 13.48: Next Generation Sequencing Market for Hospitals and Clinics in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.49: Next Generation Sequencing Market for Academic and Research Institutes in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.50: Next Generation Sequencing Market for Pharmaceutical Companies in Rest of the World, 2020-2030 (USD Billion)
  • Figure 13.51: Next Generation Sequencing Market for Other Users in Rest of the World, 2020-2030 (USD Billion)

List Of Tables

  • Table 3.1: Comparison of Available Genome Sequencing Technologies
  • Table 4.1: Genome Sequencing Service Providers: List of Industry Players
  • Table 4.2: Genome Sequencing Service Providers (Industry Players): Information on Type of Services Offered
  • Table 4.3: Genome Sequencing Service Providers (Industry Players): Information on Whole Genome Sequencing Services
  • Table 4.4: Genome Sequencing Service Providers (Industry Players): Information on Whole Exome Sequencing Services
  • Table 4.5: Genome Sequencing Service Providers (Industry Players): Information on Targeted Sequencing Services
  • Table 4.6: Genome Sequencing Service Providers: List of Non-Industry Players
  • Table 4.7: Genome Sequencing Service Providers (Non-Industry Players): Information on Type of Services Offered
  • Table 4.8: Genome Sequencing Service Providers (Non-Industry Players): Information on Whole Genome Sequencing Services
  • Table 4.9: Genome Sequencing Service Providers (Non-Industry Players): Information on Whole Exome Sequencing Services
  • Table 4.10: Genome Sequencing Service Providers (Non-Industry Players): Information on Targeted Sequencing Services
  • Table 5.1: Genome Sequencing: List of Available Technologies
  • Table 5.2: Genome Sequencing Technologies: Additional Technology Specifications
  • Table 5.3: List of Genome Sequencing Technology Providers
  • Table 7.1: BGI: Company Snapshot
  • Table 7.2: BGI Genomics: Recent Developments and Future Outlook
  • Table 7.3: Veritas: Company Snapshot
  • Table 7.4: Veritas: Recent Developments and Future Outlook
  • Table 7.5: Novogene: Company Snapshot
  • Table 7.6: Novogene: Recent Developments and Future Outlook
  • Table 7.7: GENEWIZ: Company Snapshot
  • Table 7.8: GENEWIZ: Recent Developments and Future Outlook
  • Table 7.9: Eurofins Genomics: Company Snapshot
  • Table 7.10: Eurofins Genomics: Recent Developments and Future Outlook
  • Table 7.11: CD Genomics: Company Snapshot
  • Table 7.12: CD Genomics: Recent Developments and Future Outlook
  • Table 7.13: DNA Link: Company Snapshot
  • Table 7.14: DNA Link: Recent Developments and Future Outlook
  • Table 7.15: Applied Biological Materials: Company Snapshot
  • Table 7.16: Applied Biological Materials: Recent Developments and Future Outlook
  • Table 7.17: Admera Health: Company Snapshot
  • Table 7.18: Admera Health: Recent Developments and Future Outlook
  • Table 7.19: Gene by Gene: Company Snapshot
  • Table 7.20: Gene by Gene: Recent Developments and Future Outlook
  • Table 7.21: Xcerlis Labs: Company Snapshot
  • Table 7.22: Xcerlis Labs: Recent Developments and Future Outlook
  • Table 7.23: Fulgent Genetics: Company Snapshot
  • Table 7.24: Fulgent Genetics: Recent Developments and Future Outlook
  • Table 7.25: Omega Biosciences: Company Snapshot
  • Table 7.26: Omega Biosciences: Recent Developments and Future Outlook
  • Table 7.27: Med-Genome: Company Snapshot
  • Table 7.28: Med-Genome: Recent Developments and Future Outlook
  • Table 7.29: Psomagen: Company Snapshot
  • Table 7.30: Psomagen: Recent Developments and Future Outlook
  • Table 8.1: Illumina: Recent Developments and Future Outlook
  • Table 8.2: Oxford Nanopore Technologies: Recent Developments and Future Outlook
  • Table 8.3: Thermo Fisher Scientific: Recent Developments and Future Outlook
  • Table 9.1: Patent Portfolio: CPC Symbols
  • Table 9.2: Patent Portfolio: Most Popular CPC Symbols
  • Table 9.3: Patent Portfolio: List of Top 10 CPC Symbols
  • Table 9.4: Patent Valuation Analysis: Categorization based on Weighted Valuation Scores
  • Table 9.5: Patent Portfolio: List of Relatively Higher Value Patents
  • Table 12.1: Genome Sequencing: List of Government Sponsored Initiatives
  • Table 12.2: Government Sponsored Initiatives: Information on Research Objectives
  • Table 12.3: Government Sponsored Initiatives: Additional Details
  • Table 12.4: Government Sponsored Initiatives: Information on Region-Specific Data Accessibility
  • Table 15.1: Genome Sequencing Service Providers (Industry Players): Distribution by Year of Establishment
  • Table 15.2: Genome Sequencing Service Providers (Industry Players): Distribution by Company Size
  • Table 15.3: Genome Sequencing Service Providers (Industry Players): Distribution by Geography
  • Table 15.4: Genome Sequencing Service Providers (Industry Players): Distribution by Type of Services Offered
  • Table 15.5: Whole Genome Sequencing Services (Industry Players): Distribution by Technology Used
  • Table 15.6: Whole Exome Sequencing Services (Industry Players): Distribution by Technology Used
  • Table 15.7: Targeted Sequencing Services (Industry Players): Distribution by Technology Used
  • Table 15.8: Genome Sequencing Service Providers (Non-Industry Players): Distribution by Year of Establishment
  • Table 15.9: Genome Sequencing Service Providers (Non-Industry Players): Distribution by Geography
  • Table 15.10: Genome Sequencing Service Providers (Non-Industry Players): Distribution by Type of Services Offered
  • Table 15.11: Whole Genome Sequencing Services (Non-Industry Players): Distribution by Technology Used
  • Table 15.12: Whole Exome Sequencing Services (Non-Industry Players): Distribution by Technology Used
  • Table 15.13: Targeted Sequencing Services (Non-Industry Players): Distribution by Technology Used
  • Table 15.14: Genome Sequencing Technologies: Distribution by Type of Application
  • Table 15.15: Genome Sequencing Technologies: Distribution by Maximum Sequencing Output
  • Table 15.16: Genome Sequencing Technologies: Distribution by Maximum Reads per Run
  • Table 15.17: Genome Sequencing Technologies: Distribution by Sequencing Technique
  • Table 15.18: Genome Sequencing Technology Providers: Distribution by Year of Establishment
  • Table 15.19: Genome Sequencing Technology Providers: Distribution by Company Size
  • Table 15.20: Genome Sequencing Technology Providers: Distribution by Geography
  • Table 15.21: Illumina: Annual Revenues, 2013- Q32020 (USD Million)
  • Table 15.22: Thermo Fisher Scientific: Annual Revenues, 2013-Q32020 (USD Million)
  • Table 15.23: Patent Portfolio: Distribution by Type of Patent
  • Table 15.24: Patent Portfolio: Cumulative Distribution by Publication Year
  • Table 15.25: Patent Portfolio: Distribution by Geographical Region
  • Table 15.26: Patent Portfolio: Distribution by CPC Symbols
  • Table 15.27: Leading Players: Distribution by Size of Patent Portfolio
  • Table 15.28: Patent Portfolio: Benchmarking by International Patents
  • Table 15.29: Patent Portfolio: Distribution by Geography and Type of Patent
  • Table 15.30: Patent Portfolio: Distribution by Patent Age
  • Table 15.31: Clinical Trial Analysis: Cumulative Distribution of Number of Trials by Trial Registration Year
  • Table 15.32: Clinical Trial Analysis: Distribution by Trial Registration Year and Geography
  • Table 15.33: Clinical Trial Analysis: Distribution of Number of Patients Enrolled by Study Start Year
  • Table 15.34: Clinical Trial Analysis: Distribution by Type of Sponsors / Collaborators
  • Table 15.35: Clinical Trial Analysis: Distribution by Trial Status
  • Table 15.36: Clinical Trial Analysis: Distribution by Type of Study Design
  • Table 15.37: Clinical Trial Analysis: Distribution by Target Therapeutic Area
  • Table 15.38: Clinical Trial Analysis: Distribution by Type of Application
  • Table 15.39: Clinical Trial Analysis: Distribution by Target Therapeutic Area and Type of Application
  • Table 15.40: Big Pharma Initiatives: Distribution by Type of Initiative
  • Table 15.41: Big Pharma Initiatives: Distribution by Type of Collaboration
  • Table 15.42: Big Pharma Initiatives: Distribution by Focus Area
  • Table 15.43: Leading Players: Distribution by Number of Initiatives
  • Table 15.44: Government Sponsored Initiatives: Distribution by Study Status
  • Table 15.45: Government Sponsored Initiatives: Distribution by Study Start Year
  • Table 15.46: Government Sponsored Initiatives: Distribution by Geographical Scope
  • Table 15.47: World Map Analysis of National Initiatives by Geographical Location, Year and Number of Genomes Sequenced
  • Table 15.48: Government Sponsored Initiatives: Distribution by Research Objective
  • Table 15.49: Government Sponsored Initiatives: Distribution by Focus Area
  • Table 15.50: Government Sponsored Initiatives: Distribution by Type of Players
  • Table 15.51: Government Sponsored Initiatives: Distribution by Type of Investors
  • Table 15.52: Overall Next Generation Sequencing Market, 2020-2030 (USD Billion)
  • Table 15.53: Next Generation Sequencing Market: Distribution by Key Market Segments, 2020-2030 (USD Billion)
  • Table 15.54: Genome Sequencing Products Market: Distribution by Type of Technology, 2020 and 2030 (USD Billion)
  • Table 15.55: Genome Sequencing Services Market: Distribution by Type of Service, 2020 and 2030 (USD Billion)
  • Table 15.56: Next Generation Sequencing Market: Distribution by Application Area, 2020 and 2030 (USD Billion)
  • Table 15.57: Next Generation Sequencing Market: Distribution by End-Users, 2020 and 2030 (USD Billion)
  • Table 15.58: Next Generation Sequencing Market: Distribution by Geographical Regions, 2020 and 2030 (USD Billion)
  • Table 15.59: Next Generation Sequencing Market in North America, 2020-2030 (USD Billion)
  • Table 15.60: Next Generation Sequencing Market in North America: Distribution by Application Area, 2020-2030 (USD Billion)
  • Table 15.61: Next Generation Sequencing Market for Diagnostics in North America, 2020-2030 (USD Billion)
  • Table 15.62: Next Generation Sequencing Market for Drug Discovery in North America, 2020-2030 (USD Billion)
  • Table 15.63: Next Generation Sequencing Market in for Precision Medicine in North America, 2020-2030 (USD Billion)
  • Table 15.64: Next Generation Sequencing Market in for Other Application Areas in North America, 2020-2030 (USD Billion)
  • Table 15.65: Next Generation Sequencing Market in North America: Distribution by End-Users, 2020-2030 (USD Billion)
  • Table 15.66: Next Generation Sequencing Market for Hospitals and Clinics in North America, 2020-2030 (USD Billion)
  • Table 15.67: Next Generation Sequencing Market for Academic and Research Institutes in North America, 2020-2030 (USD Billion)
  • Table 15.68: Next Generation Sequencing Market for Pharmaceutical Companies in North America, 2020-2030 (USD Billion)
  • Table 15.69: Next Generation Sequencing Market for Other Users in North America, 2020-2030 (USD Billion)
  • Table 15.70: Next Generation Sequencing Market in Europe, 2020-2030 (USD Billion)
  • Table 15.71: Next Generation Sequencing Market in Europe: Distribution by Application Area, 2020-2030 (USD Billion)
  • Table 15.72: Next Generation Sequencing Market for Diagnostics in Europe, 2020-2030 (USD Billion)
  • Table 15.73: Next Generation Sequencing Market for Drug Discovery in Europe, 2020-2030 (USD Billion)
  • Table 15.74: Next Generation Sequencing Market for Precision Medicine in Europe, 2020-2030 (USD Billion)
  • Table 15.75: Next Generation Sequencing Market in for Other Application Areas in Europe, 2020-2030 (USD Billion)
  • Table 15.76: Next Generation Sequencing Market in Europe: Distribution by End Users, 2020- 2030 (USD Billion)
  • Table 15.77: Next Generation Sequencing Market for Hospitals and Clinics in Europe, 2020- 2030 (USD Billion)
  • Table 15.78: Next Generation Sequencing Market for Academic and Research Institutes in Europe, 2020-2030 (USD Billion)
  • Table 15.79: Next Generation Sequencing Market for Pharmaceutical Companies in Europe, 2020-2030 (USD Billion)
  • Table 15.80: Next Generation Sequencing Market for Other Users in Europe, 2020-2030 (USD Billion)
  • Table 15.81: Next Generation Sequencing Market in Asia-Pacific, 2020-2030 (USD Billion)
  • Table 15.82: Next Generation Sequencing Market in Asia-Pacific: Distribution by Application Area, 2020-2030 (USD Billion)
  • Table 15.83: Next Generation Sequencing Market for Diagnostics in Asia-Pacific, 2020-2030 (USD Billion)
  • Table 15.84: Next Generation Sequencing Market for Drug Discovery in Asia-Pacific, 2020-2030 (USD Billion)
  • Table 15.85: Next Generation Sequencing Market for Precision Medicine in Asia-Pacific, 2020-2030 (USD Billion)
  • Table 15.86: Next Generation Sequencing Market for Other Application Areas in Asia-Pacific, 2020-2030 (USD Billion)
  • Table 15.87: Next Generation Sequencing Market in Asia-Pacific: Distribution by End-Users 2020-2030 (USD Billion)
  • Table 15.88: Next Generation Sequencing Market for Hospitals and Clinics in Asia-Pacific, 2020-2030 (USD Billion)
  • Table 15.89: Next Generation Sequencing Market for Academic and Research Institutes in Asia-Pacific, 2020-2030 (USD Billion)
  • Table 15.90: Next Generation Sequencing Market for Pharmaceutical Companies in Asia-Pacific, 2020-2030 (USD Billion)
  • Table 15.91: Next Generation Sequencing Market for Other Users in Asia-Pacific, 2020-2030 (USD Billion)
  • Table 15.92: Next Generation Sequencing Market in Rest of the World, 2020-2030 (USD Billion)
  • Table 15.93: Next Generation Sequencing Market in Rest of the World: Distribution by Application Area, 2020-2030 (USD Billion)
  • Table 15.94: Next Generation Sequencing Market for Diagnostics in Rest of the World, 2020-2030 (USD Billion)
  • Table 15.95: Next Generation Sequencing Market for Drug Discovery in Rest of the World, 2020-2030 (USD Billion)
  • Table 15.96: Next Generation Sequencing Market for Precision Medicine in Rest of the World, 2020-2030 (USD Billion)
  • Table 15.97: Next Generation Sequencing Market for Other Application Areas in Rest of the World, 2020-2030 (USD Billion)
  • Table 15.98: Next Generation Sequencing Market in Rest of the World: Distribution by End-Users, 2020-2030 (USD Billion)
  • Table 15.99: Next Generation Sequencing Market for Hospitals and Clinics in Rest of the World, 2020-2030 (USD Billion)
  • Table 15.100: Next Generation Sequencing Market for Academic and Research Institutes in Rest of the World, 2020-2030 (USD Billion)
  • Table 15.101: Next Generation Sequencing Market for Pharmaceutical Companies in Rest of the World, 2020-2030 (USD Billion)
  • Table 15.102: Next Generation Sequencing Market for Other Users in Rest of the World, 2020-2030 (USD Billion)

Listed Companies

The following companies and organizations have been mentioned in the report.

  • 1st base
  • 23andMe
  • AbbVie
  • AbCellera
  • Active Motif
  • Activiomics
  • Adaltis
  • Admera Health
  • Agiomix
  • AgriGenome Labs
  • AKESOgen
  • Almac Group
  • American Association for Cancer Research
  • Amgen
  • Annoroad Gene Technology
  • ANTISEL
  • Applied Biological Materials
  • Arizona Genomics Institute
  • Arizona Technology Enterprises
  • Arthritis Research UK
  • ARUP Laboratories
  • Asper Biogene
  • AstraZeneca
  • Asuragen
  • Auragen
  • Australian Genome Research Facility
  • BaseClear
  • Bayer
  • BGI
  • Bio Basic
  • BioAnalytical Services Laboratory (University of Maryland)
  • BIOFIDAL
  • Bionano Genomics
  • Biosearch Technologies
  • Biotechnology Center (University of Wisconsin)
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Broad Institute
  • C-Camp (Next Generation Genomics facility)
  • CD Genomics
  • CeGaT
  • Celsius Therapeutics
  • CEN4GEN
  • Center for Applied Genomics (Children's Hospital of Philadelphia)
  • Center for biomedical research Support (University of Texas)
  • Centogene
  • Centre for Genome Biology (University of Bologna)
  • Centre for Genomic Research (University of Liverpool)
  • Chromous
  • Cold Spring Harbor Laboratory Next Generation Genomics Core
  • Columbia Genome Center
  • Columbia University
  • Complete Genomics
  • Computomics
  • Contextual Genomics
  • CosmosID
  • Daiichi Sankyo
  • Dante Labs
  • DBS Genomics (Durham University)
  • DC3 Therapeutics
  • De Novo Genomics
  • deCODE genetics
  • DiaCarta
  • Diagnomics
  • Diversigen
  • DNA Genotek
  • DNA Link
  • DNA Sequencing & Genotyping Center Delaware Biotechnology Institute
  • DNA Sequencing and Gene Analysis Center (University of Washington)
  • DNA Sequencing Center (Brigham Young University)
  • DNAnexus
  • DNAVision
  • Dow Agrosciences
  • Earlham Institute
  • Edinburgh Genomics
  • Epigenomics Core
  • Eurofins Genomics
  • Fasteris
  • Ferring Pharmaceuticals
  • Firalis
  • Five Prime Therapeutics
  • Foundation Medicine
  • Frasergen Bioinformatics
  • Fulgent Genetics
  • Full Genomes
  • Functional Genomics Center Zurich (University of Zürich)
  • GenapSys
  • Gencove
  • Gene by Gene
  • Genentech
  • GenePlanet
  • GeneTech
  • GENEWIZ
  • Genia Technologies
  • Genialis
  • Genome
  • Genome Quebec Innovation Centre
  • Genome Technology Access Center (University of Washington)
  • GenomeFan
  • GenomeScan
  • GenomeStream
  • Genomics and Sequencing Center (University of Rhode Island)
  • Genomics Evidence Neoplasia Information Exchange
  • Genomics Medicine Ireland
  • Genomics Personalized Health
  • Genomics Sequencing Service Center (Stanford Medicine)
  • Genomix4Life
  • Genoptix
  • Genosity
  • Genotypic Technology
  • Gilead Sciences
  • GlaxoSmithKline
  • GRAIL
  • Halozyme Therapeutics
  • Harvard University
  • Health Wadsworth Center
  • Healthcare and Bioscience iNet
  • HistoGenetics
  • Horizon Discovery
  • HudsonAlpha Genome Sequencing Center
  • Human Genome Sciences
  • Human Longevity
  • Icahn Institute for Data Science and Genomic Technology
  • Illumina
  • Inotrem
  • Institute for Food Safety and Health (Illinois Institute of Technology)
  • Integrative Genomics Core (City of Hope)
  • International Wheat Genome Sequencing Consortium
  • Jan-Willem de Gier (Stockholm University)
  • Johns Hopkins University
  • Johnson and Johnson
  • Jouvene
  • Kapa Biosystems
  • Kazusa DNA Research Institute
  • KCCG Sequencing Laboratory (Garvan Institute of Medical Research)
  • LC Sciences
  • Loop Genomics
  • Loxo Oncology
  • Lucigen
  • Macrogen
  • Maryland Genomics
  • Massachusetts General Hospital
  • Massachusetts Institute of Technology
  • Massey Genome Service (Massey University)
  • Max Planck-Genome-centre Cologne
  • McDonnell Genome Institute (Washington University)
  • McGill University
  • MedGenome
  • MedImmune (a subsidiary of AstraZeneca)
  • Medivir
  • Merck
  • MGI Tech
  • Microba
  • Microgenomics
  • Microsynth
  • MNG Laboratories (Medical Neurogenetics)
  • MOgene
  • MolDiag Solutions
  • Molecular Biology and Genomics Core (Washington State University)
  • MongoDB
  • MRC Human Genetics Unit (University of Edinburgh)
  • myGenomics
  • Myriad Genetics
  • Nabsys
  • National Genomics Infrastructure (University of Uppsala)
  • National Instrumentation Center for Environmental Management
  • Nebula Genomics
  • New York Genome Center
  • Next Generation Sequencing Core (Oklahoma Medical Research Foundation)
  • Next Generation Sequencing Facility (University of Leeds)
  • Novartis
  • Novogene
  • Nucleics
  • Nucleome
  • Ocean Genome Legacy
  • Okairos and Conatus
  • Omega Bioservices
  • Oncimmune
  • OpGen
  • Otogenetics
  • Oxford Genomics Centre
  • Oxford Nanopore Technologies
  • Oxford University Consortium
  • Pacific Biosciences
  • Partners HealthCare Personalized Medicine
  • PerkinElmer Genomics
  • Pfizer
  • Phalanx Biotech
  • Phoenix Molecular Designs
  • Pierre Fabre
  • Protein and Nucleic Acid Facility
  • Psomagen
  • Q2 Solutions
  • QIAGEN
  • Quick Biology
  • Rady Children's Institute for Genomic Medicine
  • Ramaciotti Centre for Genomics (UNSW Sydney)
  • RAPiD Genomics
  • REPROCELL
  • Roche
  • RTLGenomics
  • San Diego Supercomputer Center
  • Sanofi
  • Scripps Translational Science Institute
  • Second Genome
  • SeqLL
  • SeqMatic
  • Sequencing Center
  • Shanghai OE Biotech
  • Source BioScience
  • SRM
  • Stanford University
  • StarSEQ
  • Stratos Genomics
  • Synbio Technologies
  • Technology Center for Genomics & Bioinformatics (UCLA)
  • Texas A&M AgriLife
  • Theragen Etex Bio
  • Thermo Fisher Scientific
  • Toldot Genetics
  • UCB
  • UCLA Clinical Genomics Center
  • UK's Medical Research Foundation
  • United Therapeutics
  • University of California
  • University of Leicester
  • University of London
  • University of Minnesota Genomics Center
  • University of Nottingham
  • University of Utah Health
  • Veritas
  • Waksman Institute of Microbiology (Rutgers University)
  • Wellcome Sanger Institute
  • WuXi NextCODE
  • Xcelris Labs
  • Yaazh Xenomics
  • Yale Center for Genome Analysis (Yale School of Medicine)
  • Yikon Genomics